Silence Therapeutics

Silence Therapeutics is a leading RNA therapeutics company. Its technology can selectively silence or replace the expression of any gene in the genome, modulating expression up as well as down in a variety of organs and cell types, in vivo. This allows the development of therapeutics for diseases with high unmet clinical need. Silence has developed proprietary modifications to improve the robustness of RNA sequences together with advanced liposomal chemistries to enhance the delivery of its therapeutics. Listed on London’s AIM since 2005 (AIM: SLN), and with operations in London and Berlin, Silence is one of very few listed companies globally with human validated RNA delivery systems. Its AtuRNAi® technology is one of the safest and most tested, with over 400 patients dosed and no immune response observed so far. It has been used in three Phase 2 clinical trials, two awaiting results. Delivery capability is key for the next stage in genetic medicine, targeting disease right at the cause. Silence has an expanding early stage pipeline and collaborates with world leading research institutions to develop the most promising drug candidates. For more information, visit us at www.silence-therapeutics.com, or follow us on Twitter - @SilenceTheraPlc
Company Growth (employees)
Type
Public
HQ
London, GB
Founded
1999
Size (employees)
56 (est)+10%
Silence Therapeutics was founded in 1999 and is headquartered in London, GB

Silence Therapeutics Office Locations

Silence Therapeutics has an office in London
London, GB (HQ)
72 Hammersmith Rd

Silence Therapeutics Data and Metrics

Silence Therapeutics Financial Metrics

Silence Therapeutics's revenue was reported to be £15 k in FY, 2014
GBP

Net income (FY, 2015)

(6.6 m)

Market capitalization (08-Jun-2017)

67.8 m

Closing share price (08-Jun-2017)

1

Cash (31-Dec-2015)

51.9 m
Silence Therapeutics's current market capitalization is £67.8 m.
GBPFY, 2013FY, 2014FY, 2015

Revenue

117 k15 k

Revenue growth, %

(87%)

Pre tax profit

(9 m)(12 m)(9.4 m)

Net Income

(9 m)(11.1 m)(6.6 m)
GBPFY, 2013FY, 2014FY, 2015

Cash

15.9 m16.9 m51.9 m

Accounts Receivable

375 k1.6 m

Current Assets

21.3 m22.2 m53.6 m

PP&E

218 k460 k1.3 m

Goodwill

7.8 m7.1 m6.7 m

Total Assets

29.3 m29.8 m61.5 m

Accounts Payable

476 k540 k207 k

Current Liabilities

1.7 m2 m1.1 m

Total Liabilities

1.7 m2 m1.1 m

Retained Earnings

(9 m)(11.1 m)(6.6 m)

Total Equity

27.6 m27.8 m60.4 m

Financial Leverage

1.1 x1.1 x1 x
GBPFY, 2013FY, 2014FY, 2015

Cash From Operating Activities

(6.8 m)(9.5 m)(8.3 m)

Cash From Financing Activities

18.8 m10.8 m39.2 m

Income Taxes Paid

892 k2.8 m
Y, 2015

Financial Leverage

1 x

Silence Therapeutics Market Value History

Silence Therapeutics Online and Social Media Presence

Silence Therapeutics Company Life and Culture

You may also be interested in